Navigation Links
Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing
Date:12/21/2007

NEW BRUNSWICK, N.J., December 21 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (Amex: SNT) today announced that the Company recently closed on an additional $4.0 million of its previously announced private placements with YA Global Investments, LP ("YA Global") and Stanford Venture Capital Holdings, Inc. ("Stanford"). Senesco has now closed on an aggregate of $7 million of the $10 million private placements of secured convertible debentures and warrants. Each of the next $1.5 million traunches will occur upon the Company fulfilling certain development milestones.

Senesco primarily intends to utilize the proceeds of this financing to advance its research in multiple myeloma with the goal of initiating a Phase I clinical trial. The Company estimates that it will take approximately 18-24 months to complete the steps necessary to initiate a Phase I clinical trial. Senesco believes that the proceeds from the combined $10 million private placements from YA Global and Stanford should be sufficient to allow it to complete these steps.

"We are pleased with the confidence YA Global and Stanford have shown in Senesco's ability to execute its business strategy through these private placements," said Joel Brooks, Chief Financial Officer and Treasurer of Senesco.

H.C. Wainwright acted as the placement agent for this transaction. The terms of the debentures and warrants were previously disclosed on a Form 8-K, dated August 1, 2007 and August 29, 2007 and in the Company's annual report on Form 10-K.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or s
'/>"/>

SOURCE Senesco Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
2. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
3. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
4. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
5. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
6. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
7. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
8. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
9. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
10. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
11. DNA Sequencing Equipment Market to Fragment and Grow as Competition, New Technologies Develop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... July 25, 2014 Amgen (NASDAQ: ... declared a $0.61 per share dividend for the third ... Sept. 5, 2014, to all stockholders of record as ... About Amgen Amgen is committed to ... serious illnesses by discovering, developing, manufacturing and delivering innovative ...
(Date:7/25/2014)... University of Leicester has furthered our understanding of ... create new materials using nanosized ,building blocks,. , ... prestigious academic journal Physical Review Letters , ... rich detail the structure and internal atomic motion ... and a single helium atom. , The technique ...
(Date:7/25/2014)... 25, 2014 According to a new ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... market is estimated at USD 161,056.5 million in 2014 ... 10.1% from 2014 to 2020, to reach an estimated ... biological drugs market is witnessing a significant growth due ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 The Conferee ... for Topics for Conferee Networking. These two-hour sessions provide ... to meet and resolve problems, discuss new techniques, or ... deadline to submit a topic for consideration is August ... pittcon.org . The Conferee Networking committee will review the ...
Breaking Biology Technology:Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2
... RYE, N.Y., Nov. 10 Curemark, LLC, a drug ... autism, was one of 32 biotech companies headed by ... 2009 forum, held recently in Silicon Valley, Madison, Wisconsin, ... from the U.S. and abroad applied to participate. , ...
... ... the prestigious eHealthcare Leadership Award given annually to organizations representing the best web sites ... ... provider of clinical trials information, received its fifth consecutive eHealthcare Leadership Award and seventh ...
... N.J., Nov. 10 Regado Biosciences, a privately held company leading ... Ellen McDonald, MBA, Senior Vice President and Chief Business Officer, will ... in Philadelphia, Pennsylvania. Ms. McDonald,s presentation ... Monday, November 16 and will ...
Cached Biology Technology:Curemark Presents at Springboard Enterprises Life Sciences Forum 2CenterWatch Honored a Fifth Consecutive Year for Best Healthcare Content 2Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 16, 2009 2
(Date:7/28/2014)... (July 28, 2014) Rice University researchers are ... of varying flexibility that can be used as microscale ... proof that "bead-spring" polymers, introduced as theory in the ... as required and should be of interest to materials ... The work led by Rice chemical and biomolecular engineer ...
(Date:7/28/2014)... and treat HIV infection has been problematic until now ... arouse as they get rid of the invaders. Now, ... and the National Institutes of Health (NIH) have demonstrated ... around the time of infection could have long-term ... appeared in Nature . , Interferons, named ...
(Date:7/28/2014)... Amundsen became the first man to reach the South ... later, an international team of scientists led by Joe ... that air pollution from industrial activities arrived long before. ... widely spaced locations around the Antarctic continent, including the ... precise reconstruction to date of lead pollution over the ...
Breaking Biology News(10 mins):Seeing is bead-lieving 2Interfering with interferon 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 3
... most important fruit trees in the world. Citrus has a ... 4,000 years. Until now, however, the exact genetic origins of ... lemon ( C. limon ), and grapefruit ( C. paradisi ... China has published a study in the Journal of the ...
... at Dana-Farber Cancer Institute have received a $5.6 million ... and the Army Research Office (ARO) to develop transient ... pathogens. The ultimate goal is to develop a ... of receiving it in a laboratory. Wayne A. ...
... , CHAPEL HILL, N.C. Researchers at the University of ... can make brain cells resistant to programmed cell death or ... microRNA-29 or miR-29, has already been shown to be in ... and Huntington,s disease. Thus, the discovery could herald a new ...
Cached Biology News:Genetic origin of cultivated citrus determined 2Dana-Farber receive $5.6 million grant to develop rapid countermeasures to infectious agents 2New molecule could save brain cells from neurodegeneration, stroke 2New molecule could save brain cells from neurodegeneration, stroke 3
Makes gels easy to load and track during electrophoresis. 10X concentrate of Bromophenol Blue, glycerol solution....
"BioTracker 6X Bromophenol Blue Tracking Dye is composed of 60% St DI H2O, 30% Glycerol, 10% 10XTE, 0.25% BPB Dye and 0.85% SDS....
Request Info...
Agarose, low melting/gelling temperature, high MW separation (>1000 bp), 25 g. Suitable for enzymatic modifications. Nuclease-free.Gel point: 24-30 C, EEO (-mr): 300 gm/cm2. Category: Nucleotides &...
Biology Products: